Patient characteristics | RA (n = 42) | PsA (n = 50) | ||
---|---|---|---|---|
PDUS-negative (n = 15) | PDUS-positive (n = 27) | PDUS-negative (n = 34) | PDUS-positive (n = 16) | |
Female sex, n (%) | 11 (73.3) | 23 (85.2) | 15 (44.1) | 10 (62.5)a |
Age, years, median (range) | 62 (49–78) | 64 (30–81) | 53 (33–77) | 55 (40–72) |
Disease duration, years, median (range) | 13 (8–28) | 17 (2–44) | 13.5 (1–28) | 16 (3–36) |
Concomitant csDMARD, n (%) | 11 (73.3) | 21 (77.8) | 11 (32.4) | 4 (25) |
Reduced dose, n (%) | 4 (26.7) | 8 (29.6) | 21 (61.8) | 9 (56.3) |
Calprotectin, μg/ml, median (range) | 1.44 (0.2–2.4) | 2.95 (0.2–5.5)a | 0.70 (0.06–3.7) | 2.36 (0.9–4.6)b |
CRP, mg/dl, median (range) | 0.07 (0.02–0.1) | 0.30 (0.01–1.4)a | 0.08 (0.01–0.6) | 0.09 (0.01–0.3) |
ESR, mm/h, median (range) | 10 (2–24) | 13 (2–43) | 8 (2–29) | 13 (4–32)a |
SJC, median (range) | 0 (0–1) | 0 (0–3) | 0 (0–1) | 0 (0) |
TJC, median (range) | 0 (0–1) | 0 (0–2) | 0 (0–1) | 0 (0–1) |
DAS28-ESR, median (range) | 2.08 (1.5–2.6) | 2.62 (1.3–3.2)a | 1.67 (1–2.7) | 2.15 (1.1–3.1)a |
Remission based on DAS28-ESR, n (%) | 13 (86.7) | 14 (51.9)b | 9 (90) | 6 (75)a |
Low disease activity based on DAS28-ESR, n (%) | 2 (13.3) | 13 (48.1)b | 1 (10) | 2 (25) |
SDAI, median (range) | 6.02 (2–8) | 6.26 (2–11)a | 5.10 (2–8) | 6.04 (2–8.3) |
CDAI, median (range) | 6 (2–8) | 6 (2–11) | 5 (2–8) | 6 (2–8) |
ADA trough serum levels, μg/ml, median (range) | 8.39 (4.2–12) | 1.68 (0.6–12)a | 6.95 (4.1–12) | 0.88 (0.2–9.8)a |
ETN trough serum levels, μg/ml, median (range) | 2.54 (0.2–4.7) | 0.98 (0.7–2.3)a | 1.38 (01–3.5) | 0.91 (0.6–1.6)a |
IFX trough serum levels, μg/ml, median (range) | 8.39 (4.2–12) | 1.68 (0.6–12)a | 3.21 (0.7–7.7) | 2.86 (0.1–6.5) |